MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 Patients

MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opportunities at Global Bio-Pharma Events in US and Japan

MEDIPOST Completes Administration for Phase 3 Clinical Trial of CARTISTEM® for Knee Osteoarthritis in Japan

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelerating North American Launch of CARTISTEM®